Fiscal Year 2023 Outlook
For FY 2023, Bruker is increasing revenue guidance to a range of $2.88-$2.91 billion, up from prior outlook of $2.85-$2.90 billion. Bruker’s updated revenue guidance implies 14%-15% year-over-year reported revenue growth, up from prior guidance of 12.5%-14.5%, including contributions from:
- Organic revenue growth of 11.5%-12.5%, up 150 basis points (bps) at the midpoint from prior outlook of 9.5%-11.5%,
- M&A revenue growth contribution of ~2.5%, up from prior guidance of ~2%, largely due to expected fourth quarter 2023 revenue from the Cellular Analysis business acquired on October 2, 2023,
- Constant currency (CC) revenue growth of 14%-15%, up from prior guidance of 11.5%-13.5%, and
- Foreign currency translation impact on revenue now neutral, vs. prior guidance of a 1% tailwind.
Bruker now expects FY 2023 non-GAAP EPS of $2.48-$2.53, or 6%-8% year-over-year growth. Our updated non-GAAP EPS guidance reflects a $0.05 expected increase from the core business, more than offset by a ~$0.12 negative impact from the Cellular Analysis business in the fourth quarter of 2023, resulting overall in a $0.07 decrease from prior FY 2023 guidance. Bruker is rapidly right-sizing the Cellular Analysis cost structure, with the expectation that it will be slightly dilutive in FY 2024, and accretive to our non-GAAP EPS by FY 2026. Excluding Cellular Analysis, Bruker’s updated FY 2023 guidance implies 11%-13% non-GAAP EPS growth year-over-year, up from prior guidance of 9%-11%.